Xiao Guodong, Lu Weiping, Yuan Jing, Liu Zuyue, Wang Peili, Fan Huijie
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No.1 Jianshe Dong Road, ErQi District, Zhengzhou, 450052, Henan, China.
Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, No 127 Dongming Road, Jinshui District, Zhengzhou, 450008, Henan, China.
J Transl Med. 2024 Jan 24;22(1):99. doi: 10.1186/s12967-024-04897-2.
Cancer stem cells (CSCs) are a small population of cells in tumor tissues that can drive tumor initiation and promote tumor progression. A small number of previous studies indirectly mentioned the role of F-box and WD repeat domain-containing 7 (FBXW7) as a tumor suppressor in Triple-negative breast cancer (TNBC). However, few studies have focused on the function of FBXW7 in cancer stemness in TNBC and the related mechanism.
We detected FBXW7 by immunohistochemistry (IHC) in 80 TNBC patients. FBXW7 knockdown and overexpression in MD-MBA-231 and HCC1937 cell models were constructed. The effect of FBXW7 on malignant phenotype and stemness was assessed by colony assays, flow cytometry, transwell assays, western blot, and sphere formation assays. Immunoprecipitation-Mass Spectrometry (IP-MS) and ubiquitination experiments were used to find and verify potential downstream substrate proteins of FBXW7. Animal experiments were constructed to examine the effect of FBXW7 on tumorigenic potential and cancer stemness of TNBC cells in vivo.
The results showed that FBXW7 was expressed at low levels in TNBC tissues and positively correlated with prognosis of TNBC patients. In vitro, FBXW7 significantly inhibited colony formation, cell cycle progression, cell migration, EMT process, cancer stemness and promotes apoptosis. Further experiments confirmed that chromodomain-helicase-DNA-binding protein 4 (CHD4) is a novel downstream target of FBXW7 and is downregulated by FBXW7 via proteasomal degradation. Moreover, CHD4 could promote the nuclear translocation of β-catenin and reverse the inhibitory effect of FBXW7 on β-catenin, and ultimately activate the Wnt/β-catenin pathway. Rescue experiments confirmed that the FBXW7-CHD4-Wnt/β-catenin axis was involved in regulating the maintenance of CSC in TNBC cells. In animal experiments, FBXW7 reduced CSC marker expression and suppressed TNBC cell tumorigenesis in vivo.
Taken together, these results highlight that FBXW7 degrades CHD4 protein through ubiquitination, thereby blocking the activation of the Wnt/β-catenin pathway to inhibit the stemness of TNBC cells. Thus, targeting FBXW7 may be a promising strategy for therapeutic intervention against TNBC.
癌症干细胞(CSCs)是肿瘤组织中一小部分能够驱动肿瘤起始并促进肿瘤进展的细胞。此前少数研究间接提及含F-box和WD重复结构域7(FBXW7)在三阴性乳腺癌(TNBC)中作为肿瘤抑制因子的作用。然而,很少有研究关注FBXW7在TNBC癌症干性中的功能及相关机制。
我们通过免疫组织化学(IHC)检测了80例TNBC患者的FBXW7。构建了MD-MBA-231和HCC1937细胞模型中FBXW7的敲低和过表达。通过集落形成试验、流式细胞术、Transwell试验、蛋白质印迹法和球状体形成试验评估FBXW7对恶性表型和干性的影响。采用免疫沉淀-质谱(IP-MS)和泛素化实验来寻找并验证FBXW7潜在的下游底物蛋白。构建动物实验以检测FBXW7对TNBC细胞体内致瘤潜能和癌症干性的影响。
结果显示,FBXW7在TNBC组织中低表达,且与TNBC患者的预后呈正相关。在体外,FBXW7显著抑制集落形成、细胞周期进程、细胞迁移、上皮-间质转化(EMT)过程、癌症干性并促进细胞凋亡。进一步实验证实,染色质结构域解旋酶DNA结合蛋白4(CHD4)是FBXW7新的下游靶点,FBXW7通过蛋白酶体降解使其下调。此外,CHD4可促进β-连环蛋白的核转位,并逆转FBXW7对β-连环蛋白的抑制作用,最终激活Wnt/β-连环蛋白通路。挽救实验证实,FBXW7-CHD4-Wnt/β-连环蛋白轴参与调节TNBC细胞中癌症干细胞的维持。在动物实验中,FBXW7降低了癌症干细胞标志物的表达,并在体内抑制了TNBC细胞的致瘤性。
综上所述,这些结果表明FBXW7通过泛素化降解CHD4蛋白,从而阻断Wnt/β-连环蛋白通路的激活,抑制TNBC细胞的干性。因此,靶向FBXW7可能是一种有前景的TNBC治疗干预策略。